C-LANT Drainage Port Life Saving Technology for Thoracic Trauma Treatment and Post Operative Drainage
- Coordinator
- Vigor Medical Technologies Ltd, Israel
- Runs
- 1 March 2023 to 30 November 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190118979
What the project is doing
In the project's own words, from its summary on CORDIS.
Thoracic trauma is the 1st cause of accidental death globally, with a mortality rate of 60% in polytraumatic patients. The time of treatment is crucial. 80% of patients can be potentially saved if they are treated in 1h. However, current solutions to treat it are limited and static for the last 30-50 years. C-LANT is a unique self-fixating, a-traumatic and multifunctional device tackling this unmet need by offering a safe, fast, easy to use, multifunctional and cost-effective tool for treating any type of chest trauma or postoperative drainage following major thoracic and abdominal procedures.
It reduces the procedure time by 20x and saves up to €2.6Bn associated with additional tube replacement (EU). With the EIC support Vigor aims to accelerate the clinical validation and scaling-up of C-LANT, providing a global impact to healthcare systems, clinicians, and patients. C-LANT will be part of the growing Emergency Medical Devices and the Surgical Drains markets (total valued >40B -2030)
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Vigor Medical Technologies Ltd | Haifa | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI